Spotlight on MASH (Formerly NASH): Exploring the Pathophysiology and Metabolic Impairments of a Progressive Liver Disease

Description

Supported by: Novo Nordisk

Join us as we review the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH, non-alcoholic steatohepatitis), including the impact of underlying metabolic comorbidities. We will also explore the importance of early diagnosis and intervention for high-risk patients, review current management strategies and highlight the need for future therapies.

Presenter:

Mazen Noureddin, MD, MHSc